TVTX (Travere Therapeutics) Common Stock: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TVTX Travere Therapeutics Inc TVTX
61 GF Score
Price $65.71
GF Value $36.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Travere Therapeutics Common Stock?

Travere Therapeutics TVTX +1.96% 61 Common Stock is $0.0 Mil as of Jun. 2026. GuruFocus rates TVTX with a GF Score™ of 61/100 and a GF Value™ of $36.75 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Travere Therapeutics's quarterly common stock stayed the same from Dec. 2025 ($0.0 Mil) to Mar. 2026 ($0.0 Mil) and stayed the same from Mar. 2026 ($0.0 Mil) to Jun. 2026 ($0.0 Mil).

Travere Therapeutics's annual common stock increased from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil) but then stayed the same from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($0.0 Mil).

Travere Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Travere Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Travere Therapeutics Common Stock Chart

Travere Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Travere Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
TVTX
61GF Score
Travere Therapeutics Inc TVTX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Travere Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.0 Mil mean?
Travere Therapeutics (TVTX) has a Common Stock of $0.0 Mil as of Jun. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Travere Therapeutics and its competitors.
Is Travere Therapeutics' Common Stock too high?
Travere Therapeutics' current Common Stock is $0.0 Mil. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' Common Stock compare to ORKA and DNTH?
Travere Therapeutics' Common Stock of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Travere Therapeutics and its competitors. Travere Therapeutics's current Common Stock is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $36.75, compared to a current price of $65.71 — trading 78.8% above its estimated fair value. The current Common Stock is $0.0 Mil. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current Common Stock is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Travere Therapeutics (TVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued. The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75. GuruFocus considers Travere Therapeutics to be Significantly Overvalued.

Key valuation signals for TVTX:

  • Common Stock: $0.0 Mil
  • GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Travere Therapeutics Business Description

Address 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score

Get the complete analysis for TVTX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.71
Price
$36.75
GF Value